Canada Pension Plan Investment Board Buys 106,488 Shares of Becton, Dickinson and Company $BDX

Canada Pension Plan Investment Board increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 190.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 162,430 shares of the medical instruments supplier’s stock after acquiring an additional 106,488 shares during the period. Canada Pension Plan Investment Board owned 0.06% of Becton, Dickinson and Company worth $24,581,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BDX. Larson Financial Group LLC grew its holdings in Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the last quarter. Atlantic Union Bankshares Corp lifted its stake in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after buying an additional 57 shares during the last quarter. Elevation Point Wealth Partners LLC lifted its stake in shares of Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 60 shares during the last quarter. BOK Financial Private Wealth Inc. boosted its holdings in shares of Becton, Dickinson and Company by 7.3% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 73 shares during the period. Finally, Keating Financial Advisory Services Inc. grew its stake in Becton, Dickinson and Company by 41.6% in the 2nd quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 74 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $189.71 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market cap of $52.27 billion, a PE ratio of 57.14, a price-to-earnings-growth ratio of 13.26 and a beta of 0.19. The firm has a fifty day moving average price of $166.14 and a two-hundred day moving average price of $160.53. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 11,869 shares of company stock worth $1,994,719. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Bank of America dropped their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. The Goldman Sachs Group cut their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.